What a New Randomized Trial Found About Sativex and Appetite Hormones in Older Adults
| Audience | Geriatric and palliative care clinicians, endocannabinoid-focused researchers, caregivers of older adults with poor appetite, and cannabis-science readers evaluating appetite-stimulant claims |
| Primary Topic | a randomized crossover trial testing Sativex versus placebo on appetite hormones and subjective appetite in older adults with poor appetite |
| Source | Read the full source |
Sativex and Appetite Hormones in Older Adults: What a New Randomized Trial Found
A July 11, 2026 randomized, double-blind, placebo-controlled crossover trial in 17 adults age 65 and older with poor appetite found no statistically significant effect of a single Sativex dose on GLP-1, total ghrelin, or subjective appetite compared with placebo. The trial is well designed but small, so it reads as an honest null result rather than proof that cannabis-based medicines cannot help appetite in this population.
| Study Type | Randomized, double-blind, placebo-controlled crossover trial (protocolized secondary analysis) |
| Population | 17 adults age 65 and older with poor appetite |
| Intervention | Single dose of Sativex (8.1 mg THC / 7.5 mg CBD) versus placebo on two separate study days |
| Primary Outcomes | Postprandial GLP-1 and total ghrelin after one dose plus a standardized breakfast; subjective appetite via visual analog scale across two doses, breakfast, and an ad libitum lunch |
| Key Result | No statistically significant differences between Sativex and placebo for GLP-1, total ghrelin, or subjective appetite |
| THC/Metabolite Association | Higher plasma THC and metabolite levels trended toward lower GLP-1 and subjective appetite and higher ghrelin, but none of these associations reached statistical significance |
| Trial Registration | ClinicalTrials.gov NCT05503147; EudraCT 2021-002318-15 |
| Journal | Nutrients |
| Published | July 11, 2026 |
| PMID | 42514343 |
| DOI | 10.3390/nu18142274 |
This was a secondary analysis of a double-blind, randomized, placebo-controlled crossover trial in 17 adults age 65 and older who had poor appetite, a common problem tied to malnutrition risk in this age group.
Participants received a single dose of Sativex (8.1 mg THC and 7.5 mg CBD) or placebo on two separate visits. The investigators measured postprandial GLP-1 and total ghrelin after one dose plus a standardized breakfast, and tracked subjective appetite on visual analog scales through two doses, breakfast, and an ad libitum lunch.
Compared with placebo, Sativex produced no statistically significant difference in GLP-1 (estimated 2.38 pmol/L reduction; 95% CI -0.71 to 5.46; Bonferroni-corrected p = 0.274) or in the time course of total ghrelin (Bonferroni-corrected p = 0.054).
Subjective appetite ratings were also essentially unchanged, with a combined appetite score just 5.2 mm lower than placebo on a visual analog scale (95% CI -24.4 to 4.0; p = 1.00) and every individual appetite sensation showing a Bonferroni-corrected p value of 1.00.
The trial enrolled only 17 participants, which is not enough statistical power to rule out a real but modest effect, and several confidence intervals were wide enough to be compatible with either a meaningful change or none at all.
Higher plasma THC and metabolite concentrations trended toward lower GLP-1 and subjective appetite and higher ghrelin, but the authors report that none of these dose-response associations reached statistical significance either, so this should not be read as evidence of a hidden dose-dependent benefit.
For clinicians who have offered or considered Sativex as an appetite stimulant in older, frail, or malnourished patients, this trial does not provide hormonal or subjective evidence to support that specific use.
Poor appetite in older adults is multifactorial, and this study suggests that whatever benefit patients might report anecdotally with cannabis-based medicines for appetite likely does not run primarily through acute changes in GLP-1, ghrelin, or single-dose subjective hunger ratings in this population.
Cannabis-based medicines are sometimes proposed as appetite stimulants for older adults with malnutrition risk, extrapolating from THC’s known effects on hunger in younger or different clinical populations. This trial is one of relatively few attempts to test that extrapolation directly, using objective appetite-regulating hormones alongside subjective appetite ratings in a geriatric population.
The result fits a broader pattern in cannabis appetite research: effects that appear plausible from receptor biology and from younger or disease-specific populations do not always replicate cleanly when tested rigorously in a different population, such as older adults with age-related appetite loss rather than cachexia from cancer or HIV.
This is exactly the kind of trial our field needs more of: small, honest, and willing to report a null result instead of reaching for a secondary comparison that happens to clear significance. A well-designed negative trial is more useful to clinicians than an underpowered positive one, because it keeps us from overpromising a mechanism the data do not support.
My practical takeaway is that I would not counsel a patient that Sativex works as an appetite stimulant in older adults through GLP-1 or ghrelin based on this evidence. If a patient in this age group reports improved appetite with a cannabis-based medicine, that may still be a real, individually meaningful effect, but this trial suggests it is not reliably explained by the hormonal pathway the investigators tested, and clinicians should keep expectations modest and grounded in this population’s evidence rather than extrapolating from younger patients.
How to Read a Well-Designed Negative Cannabis Trial Without Overcorrecting
Negative trials are easy to misread in both directions. Some readers dismiss them because the sample is small, while others treat a null result as final proof that a mechanism does not exist.
A better approach is to ask what the trial’s design could and could not detect, and to separate a null finding here from a claim that no effect exists anywhere.
A Four-Step Reading Frame
Start With the Design's Power
A double-blind, placebo-controlled crossover trial is a strong design, but with only 17 participants it is underpowered to detect a modest true effect, which limits how confidently a null result can be generalized.
Separate Statistical Significance From Clinical Certainty
Wide confidence intervals around the GLP-1, ghrelin, and appetite estimates mean the true effect could be closer to meaningful or closer to none. A nonsignificant result here is not equivalent to definitive proof of no effect.
Note What Was and Was Not Tested
This trial tested a single dose of Sativex against placebo in older adults with poor appetite. It did not test repeated dosing, other formulations, or the younger or disease-specific populations where cannabis appetite effects have been studied before.
Translate Into Counseling, Not Prediction
The result supports caution about promising a hormonal appetite-stimulating effect from Sativex in this specific population, without ruling out that some patients may still experience a subjective benefit worth monitoring individually.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
This Trial Does Not Prove Sativex Won't Help You Personally
If you are an older adult with poor appetite, this trial does not close the door on cannabis-based medicine helping you, but it also does not provide hormonal proof that it will.
The honest message is that a single dose of Sativex did not produce a measurable change in appetite hormones or appetite ratings in this small study, so any decision to try it should be made with realistic expectations and close follow-up rather than an assumption that it works like an appetite switch.
Poor Appetite in Older Adults Needs a Broader Workup
Poor appetite in older adults is rarely explained by one mechanism. Medication effects, depression, dentition, taste changes, chronic disease, and social factors all contribute alongside any endocannabinoid signaling.
This trial suggests that a single dose of a THC/CBD product is not a reliable quick fix for the appetite-hormone piece of that puzzle, which supports keeping cannabis as one option among a broader geriatric nutrition assessment rather than a first-line hormonal therapy.
GLP-1 and Ghrelin Did Not Move as Hypothesized
The biological rationale for testing Sativex here was sound: GLP-1 and ghrelin are established appetite-regulating hormones, and THC has plausible endocannabinoid-mediated effects on both.
In this trial, however, neither hormone changed significantly after a single dose compared with placebo, and the dose-response relationship between plasma THC and these hormones also did not reach significance, which argues against a simple, easily detectable single-dose hormonal mechanism in this population.
Manage Expectations Before Recommending Sativex for Appetite
Clinicians considering Sativex specifically for appetite stimulation in older, frail patients should know that the best available randomized evidence in this population did not find a significant hormonal or subjective appetite effect from a single dose.
That does not mean the medication has no role in appropriate patients, but it argues against presenting appetite stimulation as an established, mechanism-confirmed benefit when counseling this age group.
Small Samples Cut Both Ways
A skeptical reader should notice that 17 participants is a small trial, and small trials can miss real effects just as easily as they can produce false positives.
The wide confidence intervals here, some of which come close to but do not cross into statistical significance, mean this result should temper enthusiasm without being treated as a closed case.
Appetite Loss in Aging Populations Remains a Real Problem
Poor appetite and malnutrition risk in older adults is a meaningful public-health concern, and there is understandable interest in low-risk pharmacologic options.
This trial is a reminder that promising biological rationale does not automatically translate into a measurable population-level benefit, and that rigorous testing in the specific population of interest, here older adults rather than cancer or HIV patients, is necessary before broad recommendations are made.
Multiple Comparisons and a Secondary Analysis Design
This was a protocolized secondary analysis of a larger crossover trial, and the investigators appropriately applied Bonferroni correction across multiple comparisons, which is a methodological strength but also makes it harder to reach significance with a small sample.
Readers should also note this measured only a single dose rather than sustained dosing, which limits what can be concluded about real-world, repeated-use appetite effects.
What Would Strengthen This Evidence
A larger, adequately powered trial in older adults with poor appetite, ideally with repeated dosing over days to weeks and longer-term outcomes like weight and nutritional status, would help clarify whether a real but modest effect exists.
Until that evidence exists, this trial stands as a careful, well-designed but underpowered null result rather than a final answer about Sativex and appetite hormones in aging.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Did this trial find that Sativex improves appetite in older adults?
No. The trial found no statistically significant difference between Sativex and placebo in subjective appetite ratings or in the appetite hormones GLP-1 and total ghrelin.
What was Sativex compared with in this study?
Sativex was compared with placebo in a double-blind, randomized, crossover design, so each participant received both a Sativex dose and a placebo dose on separate study days.
How many people were in this trial?
The analysis included 17 adults age 65 or older with poor appetite.
What dose of Sativex was used?
Participants received a single dose containing 8.1 mg THC and 7.5 mg CBD.
What outcomes did the researchers measure?
They measured postprandial GLP-1 and total ghrelin after one dose and a standardized breakfast, and tracked subjective appetite using visual analog scales across two doses, breakfast, and an ad libitum lunch.
Did higher THC levels in the blood predict a bigger appetite effect?
Higher plasma THC and metabolite concentrations trended toward lower GLP-1 and subjective appetite and higher ghrelin, but none of these associations reached statistical significance.
Is this trial proof that cannabis-based medicines cannot help with appetite in older adults?
No. The trial is a well-designed but small negative result. It could not detect a statistically significant effect, but its size and wide confidence intervals mean it cannot rule out a real, modest effect either.
Was this trial registered?
Yes. It is registered at ClinicalTrials.gov (NCT05503147) and EudraCT (2021-002318-15).
Where was this study published?
It was published in Nutrients on July 11, 2026, as a protocolized secondary analysis of a double-blind, randomized, placebo-controlled crossover trial.
What is the most practical takeaway for clinicians?
Clinicians should not present Sativex as a proven hormonal appetite stimulant in older adults based on current evidence, and should set realistic expectations while continuing to evaluate poor appetite through a broader geriatric lens.
